

# GOG-0209 NCTN/NCORP QoL DATA ARCHIVE

Data as of: March 25, 2013

## # Notes

- 1 Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).
- 2 Doi: 10.1200/jco.20.01076.
- 3 PMID: 33078978.
- 4 Clinical trial information: NCT00063999.
- 5 Dataset ID: NCT00063999-D2.
- 6 Unless otherwise specified, periods indicate missing data.
- 7 Data can be used to approximate published study findings, but exact reproduction of previous manuscripts may not be possible in some cases (e.g., when data must be modified for de-identification purposes or have undergone further data cleaning).

Var 1	Type	Label
upi	C	Universal patient ID
Var 2	Type	Label
toi	N	FACT-En TOI score. Range 0-120. A larger score suggests better QOL. Blank values indicate missing data.
Var 3	Type	Label
qol	N	QOL Score (PWB+FWB). Range 0-56. A larger score suggests better QOL. Blank values indicate missing data.
Var 4	Type	Label
ntx	N	FACT/GOG-Ntx subscale score (4 items). Range 0-16. A larger score suggests less neurotoxicity. Blank values indicate missing data.
Var 5	Type	Label
qol_time	N	QOL assessment time point.

Code	Definition
------	------------

1	Baseline
2	6 Weeks
3	15 Weeks
4	26 weeks

<b>Var 6</b>	<b>Type</b>	<b>Label</b>
form_valid	N	Valid QOL/PRO assessment completed by an alive patient at current time point.

<b>Code</b>	<b>Definition</b>
-------------	-------------------

0	No
---	----

1	Yes
---	-----

<b>Var 7</b>	<b>Type</b>	<b>Label</b>
qol_eval	N	Patients who were enrolled prior to March 26, 2007 and completed baseline and at least one follow-up QOL assessments were evaluable for QOL/PRO outcomes.

<b>Code</b>	<b>Definition</b>
-------------	-------------------

0	No
---	----

1	Yes
---	-----